Biosimilars Market Update
|
|
- Hilary Malone
- 5 years ago
- Views:
Transcription
1 Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto Moderator: Suzanne Lepage Suzanne Lepage Consulting, Inc. March 23, 2016
2 Agenda Why are we discussing biosimilars? Biosimilars overview What is happening in the rest of the world with biosimilars? Payer Considerations Biosimilars In Private Drug Plans Biosimilars Market Update 2
3 Panel Panelist Perspective Matthew Brougham Consultant Economist, Brougham Consulting Inc. Public Policy Mark Jackson Pharmacist, TELUS Health Private Drug Plan Manager Dr. Ed Keystone Rheumatologist, Professor of Medicine, University of Toronto Prescriber Biosimilars Market Update 3
4 1 Why are we discussing Biosimilars?
5 Why are we discussing Biosimilars? Biosimilars may offer potential cost relief from the brand name biologic medications and result in drug plan savings Biosimilars present unique regulatory and reimbursement challenges In 2015 TELUS Health adjudicated $703.2 million for biologic drugs 19% of the total eligible drug costs 2.6% of total claims Biosimilars Market Update 5
6 2 Biosimilars overview
7 What s in a name? Region Term Substitution? Canada: Subsequent Entry Biologic (SEB) No US: Biosimilar Standards Not Developed Europe: Follow on Biologic No Australia: Biosimilar Yes, In Some Cases Biosimilars Market Update 7
8 What s in a name? Term What? Who? Interchange or Generic Substitution Replace brand product with interchangeable generic Pharmacist Switching or Therapeutic substitution Replace a product with a different one Prescriber Biosimilars Market Update 8
9 What Health Canada Says Health Canada definition: An SEB is a biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. 1 Biosimilars are similar......but not identical to the original medicine 1 Health Canada Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs), 2010/03/05 Biosimilars Market Update 9
10 Size & Complexity Small Molecule Drugs & Proteins Small Molecule Drug Large Molecule Drug Large Biologic Aspirin 21 atoms hgh ~ 3000 atoms lgg Antibody ~ 25,000 atoms Size Bike ~ 20 lbs Car ~ 3000 lbs Business Jet ~ 30,000 lbs (without fuel) Complexity Biosimilars Market Update 10
11 Chemical Drug Laboratory Biologic Drug Laboratory Biosimilars Market Update 11
12 Chemical Drugs Biologics Generic Drug Biosimilar Submission Abbreviated new drug submission New drug submission requires clinical trials. Bioequivalence Pharmacist Substitution Physician authorize Biosimilars Market Update 12
13 Biosimilars Approved in Canada Brand Reference Biosimilar Biosimilar Approval Date Discount Genotropin Omnitrope 4/20/ % Remicade Inflectra 1/15/ % Lantus Basaglar 9/1/ % Neupogen Grastofil 12/7/ % Biosimilars Market Update 13
14 Indication Extrapolation Biosimilar is approved for each of the same indications as a branded originator Regardless of whether clinical testing has been carried out for each indication *First Canadian SEB Approved under new guidance January 15, 2014 Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Psoriasis Crohn s Disease (Adult) Crohn s Disease (Pediatric) Ulcerative Colitis (Adult) Ulcerative Colitis (Pediatric) REMICADE INFLECTRA (extrapolated) (extrapolated) March 11, CADTH request for input from for Inflectra (infliximab) for Crohn s disease and Ulcerative Colitis (by May 2, 2016). Submission date April 8, 2016 (Tentative) Biosimilars Market Update 14
15 Brand Name Earliest Patent Expiry Date Biosimilar Pipeline Last Patent Expiry Date Potential Biosimilar Approval Enbrel February 2023 Summer 2016 Humira Feb 2017 April 2025 February 2017 Neulasta July Eprex May or later Lucentis March 2016 April 2018 April 2018 Erbitux March Herceptin August 2017 May 2021 August 2017 or later Avastin April 2018 April 2018 April 2018 Rituxan June 2018 August 2020 June 2018 Biosimilars Market Update 15
16 Brand Name Earliest Patent Expiry Date Biosimilar Pipeline Last Patent Expiry Date Potential Biosimilar Approval Enbrel February 2023 Summer 2016 March 9, 2016 CADTH Call for Patient Input: SEB for Etanercept (Enbrel) CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). Humira Feb 2017 April 2025 February 2017 Neulasta July Eprex May or later Lucentis March 2016 April 2018 April 2018 Erbitux March Herceptin August 2017 May 2021 August 2017 or later Avastin April 2018 April 2018 April 2018 Rituxan June 2018 August 2020 June 2018 Biosimilars Market Update 16
17 Prescriber Perspective
18 3 What is happening in the rest of the world with biosimilars?
19 United States Biosimilar product : approved based on showing it is highly similar to an FDA-approved biological product Interchangeable biological product Biosimilar to an FDA-approved reference product Meets additional standards for interchangeability (in development) First biosimilar approved (March ) Zarxio (filgrastim-sndz) biosimilar to Amgen Inc. s Neupogen (filgrastim) Approved as biosimilar - not as an interchangeable product. Biosimilars Market Update 19
20 Indication Extrapolation (United States) FDA advisory committee recommended approval of Celltrion s infliximab biosimilar, CT-P13, for the same indications as its reference product, Remicade (February 9, 2016) *First Canadian SEB Approved under new guidance January 15, 2014 Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Psoriasis Crohn s Disease (Adult) Crohn s Disease (Pediatric) Ulcerative Colitis (Adult) Ulcerative Colitis (Pediatric) REMICADE INFLECTRA (extrapolated) (extrapolated) Biosimilars Market Update 20
21 Australia Brands that can be substituted by the pharmacist when dispensed are indicated in the Schedule of Pharmaceutical Benefits by an a-flag Biosimilar for listing on the PBS will consider whether the biosimilar and reference medicine should be substitutable will only recommend that substitution be allowed where the clinical evidence supports this Brand Biosimilar a-flag Remicade (infliximab) Inflectra (infliximab) Approved Neupogen (filgastrim) Nivestim (filgastrim) Rejected Lantus (insulin glargine) Basaglar (insulin blargine) Under consideration Biosimilars Market Update 21
22 United Kingdom Introducing biosimilar versions of infliximab: Inflectra and Remsima Summary of issues considered of significance to the NHS, but not NICE guidance Not presented as best practice but as real-life examples of how NHS sites have planned and managed the introduction of biosimilars. 1. University Hospital Southampton NHS Foundation Trust - Inflammatory Bowel Disease (IBD) Safe switch program started in April University College London Hospitals NHS Foundation Trust - Agreement reached for patients starting a new course of infliximab in the IBD service to be prescribed a biosimilar Biosimilars Market Update 22
23 Norway The NOR-SWITCH Study The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis. Estimated Study Completion Date: January Biosimilars Market Update 23
24 Canadian Impact
25 4 Payer Considerations
26 Public Payer Reviews of Biosimilars Reviewer Date Recommendations CADTH/CDR December 23, 2014 Inflectra listed in accordance with Health Canada approved indications List in a manner similar to Remicade Quebec February 1, 2015 British Columbia February 19, 2016 Ontario February 25, 2016 Lowest price method (LPM) Reimbursement of Remicade allowed for patients who received before April 24, 2015 NEW patients covered for Inflectra only Patients who previously received Special Authority coverage for Remicade will continue to receive coverage Inflectra added as Limited Use (LU) for new and existing patients No new requests for Remicade Patients who have an existing EAP approval for Remicade can continue coverage Biosimilars Market Update 26
27 Pharmacy regulatory authorities (switching) Provinces regulate when pharmacists can switch drugs without consulting the prescribing physician Health Canada recommended against the automatic substitution of an originator with a biosimilar. Only AB has made a statement about biosimilars subsequent entry biologics are not eligible for review as interchangeable products Biosimilars Market Update 27
28 5 Potential Impact on Private Drug Plans
29 What policies will encourage use of biosimilars in private drug plans? Biosimilars are different than traditional generic drugs Traditional drug plans will NOT generate savings from biosimilars Pharmacist can t automatically switch to biosimilar What strategies should plan sponsors consider to encourage biosimilar use? Biosimilars Market Update 29
30
Trends in Medication Management. Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management
Trends in Medication Management Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management Agenda Drug Claims Trends Legislative / Public Plan Initiatives Biosimilars Pipeline Focus on Oncology
More informationAN UPDATE ON SEBS SUMMER SEBs in the pipeline. Let s review... What s Inflectra?
SUMMER 2016 AN UPDATE ON SEBS Since we first covered subsequent-entry biologic drugs (SEBs), or biosimilars, in our fall 2014 issue of Follow the Script, this hot topic has gotten even hotter. Back then
More informationThis presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America
This presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America The development of this presentation was supported in 2016 by a sponsorship
More informationRegulation of Biosimilars in Canada
Regulation of Biosimilars in Canada Session 2: Global Regulatory Trends of Biosimilars GBC 2018 June 28, 2018 Stephanie Hardy Office of Policy and International Collaboration Biologics and Genetic Therapies
More informationAn update on development strategies of recently approved biosimilars in Europe. Johanna Mielke
An update on development strategies of recently approved biosimilars in Europe Johanna Mielke Acknowledgement & disclaimer This project was supported by the Swiss State Secretariat for Education, Research
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More informationWhy even have this talk? Disclosures. What will biosimilars mean for us? Annual Revenue Due to Adalimumab. Biosimilars 2017: What We Need to Know
Biosimilars 2017: What We Need to Know Why even have this talk? Miguel Regueiro, M.D. Professor of Medicine IBD Clinical Medical Director Senior Medical Lead, Specialty Medical Homes University of Pittsburgh
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationThe Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh
More informationBiosimilars 101: How similar are they?
Biosimilars 101: How similar are they? Matthew Marston, Pharm.D., BCPS, BCOP Senior Manager of Clinical Pharmacy Services Miller Drug, LLC Outline Describe the approval and manufacturing process of biologics
More informationHospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies
Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market
More information: Regulation of biosimilars and success factors for uptake in clinical practice. Steinar Madsen, MD, FACP(Hon) Medical director
2018-02-08: Regulation of biosimilars and success factors for uptake in clinical practice Steinar Madsen, MD, FACP(Hon) Medical director steinar.madsen@legemiddelverket.no Drug costs in Norway Billion
More informationNaming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationLife Sciences. Key issues for senior life sciences executives
Life Sciences 2016 Key issues for senior life sciences executives Biosimilars in Canada: at a tipping point J Bradley White and Nathaniel Lipkus Osler, Hoskin & Harcourt LLP Helping you unlock the value
More informationASBM Biosimilars. Canada Prescribers and Biosimilars October, Kevin Olson, CEO Industry Standard Research
ASBM Biosimilars Canada Prescribers and Biosimilars October, 2017 Kevin Olson, CEO Industry Standard Research KevinO@ISRreports.com Table of contents Page 3 Methodology 5 Sample Characteristics 6 Executive
More informationImplementation of Biosimilars: The Good, the Bad, the Ugly September 13, Learning Objectives. Audience Response 9/3/2018
Implementation of Biosimilars: The Good, the Bad, the Ugly September 13, 2018 Monica Macik, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Hematology/Oncology Eskenazi Health Indianapolis, IN Karen Smethers,
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationBiosimilar medicines: practical EU experience and perspectives. 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe
Biosimilar medicines: practical EU experience and perspectives 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe Medicines For Europe VISION Medicines for Europe Vision 2020 Our
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Answers to commonly asked questions about biosimilar versions of infliximab February 2015 (revised April 2015) Authored by Nicola Hooker (Nicola.Hooker@gstt.nhs.uk)
More informationBiosimilar Monoclonal- a reality
Biosimilar Monoclonal- a reality 2 nd MENA Regulatory Conference on Bioequivalence, Biowaivers, BIOANALYSIS, DISSOLUTION AND BIOSIMILARS Jordan DATE September 15-17, 2015 PRESENTED BY Rodeina Challand
More informationTrends in Medication Management
Trends in Medication Management Cory Cowan, Pharm.D. Director Professional Services, TELUS Health Content Outline I. Therapy class review 2017 II. Legislative updates III. Biosimilars IV. Drug pipeline
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationRE: Considerations in Demonstrating Interchangeability With a Reference Product; Draft Guidance for Industry; Availability (FDA 2017 D )
May 19, 2017 Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Considerations in Demonstrating Interchangeability With a Reference
More informationThe New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products
The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products Table of Contents Executive Director s Note Innovation & Access Biosimilars 101 Safety & Sameness How
More informationHow are biosimilars assessed and approved?
How are biosimilars assessed and approved? Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific Advice
More informationcontinuing education for pharmacists
continuing education for pharmacists Biologics and Biosimilars Volume XXXV, No. 8 Mona T. Thompson, R.Ph., PharmD, BCPS Dr. Mona Thompson has no relevant financial relationships to disclose. Goal. The
More informationBiosimilars. Their regulatory status and their use
Biosimilars Their regulatory status and their use Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Biosimilars for IBD: What the Gastroenterologist Needs to Know Tara Altepeter, MD Clinical Team
More informationTOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017
TOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017 FINANCIAL INTEREST DISCLOSURE (OVER THE PAST 24 MONTHS) Speaker: Janssen,
More informationNHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars
NHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars Angela McFarlane Market Development Director, QuintilesIMS Angela.McFarlane@QuintilesIMS.com Copyright 2016 QuintilesIMS.
More informationWhat is a biosimilar and how does sound biosimilar use look like?
Vs14f17 LBP Opleidingsinstituut voor Care & Cure: Biosimilars in the Market; what does it mean for us? Rotterdam, June 18, 2014. What is a biosimilar and how does sound biosimilar use look like? Arnold
More informationThijs J Giezen, PharmD, MSc, PhD The Netherlands
Thijs J Giezen, PharmD, MSc, PhD The Netherlands Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, The Netherlands Member of the Biosimilar Medicinal Product Working Party of European
More informationUBCM Conference. Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016
UBCM Conference Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016 Agenda Drug Landscape Private drug plan trends Cost drivers Specialty Drugs Drug Trends Top Therapeutic Classes Drug Plan
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationThe Future of the U.S. Biosimilars Market: Development, Education, and Utilization. October 18, 2016
The Future of the U.S. Biosimilars Market: Development, Education, and Utilization October 18, 2016 ABOUT THE DUKE MARGOLIS CENTER FOR HEALTH POLICY The Duke-Robert J. Margolis, MD, Center for Health Policy,
More informationUnderstanding The World Of Specialty. And Why We Should Care?
Understanding The World Of Specialty Drugs And Why We Should Care? What Are Specialty Drugs? Specialty Drugs are drugs used for the treatment of complex conditions and they often require special storage,
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationBiosimilars Update 4/23/2015. The Biosimilar Roadmap From concept to delivery. Conflict of Interest Disclosure. Collaborate Cultivate Educate
Collaborate Cultivate Educate Biosimilars Update Conflict of Interest Disclosure We have no actual or potential conflict of interest in relation to this program and presentation. Brad Patten Patrick Leary
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationThe evidence for switching stable patients to Inflectra
The evidence for switching stable patients to Inflectra Professor Silvio Danese Symposium co-chair Date of preparation: March 2017 PP-IFA-GLB-0551 Disclosures Silvio Danese has served as speaker, consultant
More informationWhat Is a Biosimilar?
Learning Objectives Compare and contrast biosimilars to their reference product and generic therapies in terms of structure, manufacturing, regulatory pathway, and clinical properties Evaluate evolving
More informationSwitching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far Authors: *Anna La Noce, 1 Marcin Ernst 2 1. General Medicine, Syneos Health, Saronno,
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION INFLIXIMAB (Inflectra Hospira Healthcare Corporation) Indications: Crohn Disease and Ulcerative Colitis Please refer to the CADTH Canadian Drug
More informationClinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View)
Athens, May 25, 2018 Clinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View) Vs18e28 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy &
More informationBIOSIMILARS: CHALLENGES AND OPPORTUNITIES
BIOSIMILARS: CHALLENGES AND OPPORTUNITIES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-255-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion of this
More informationBiosimilars today or tomorrow?
Oxford Inflammatory Bowel Disease MasterClass Biosimilars today or tomorrow? Dr Vipul Jairath Bsc DPhil MRCP NIHR Clinical Lecturer Translational Gastroenterology Unit University of Oxford John Radcliffe
More informationREFERENCE CODE GDHC268CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC268CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in China The Rheumatoid Arthritis
More informationThe Potential For Litigation In New Era Of Biosimilars
The Potential For Litigation In New Era Of Biosimilars By Christian Frois, Richard Mortimer and Alan White; Analysis Group, Inc. Law360, New York (September 20, 2016, 4:06 PM EDT) Christian Frois Richard
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More informationAn innovative solution to the rising cost of drug-benefit plans
An innovative solution to the rising cost of drug-benefit plans INTRODUCED BY Biologics Savings Partnership CANADIAN DRUG PLAN SPENDING ON SPECIALTY DRUGS, INCLUDING BIOLOGICS, CONTINUES TO INCREASE 1,2
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationUnderstanding Biosimilars and Projecting the Cost Savings to Employers Update
Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary
More informationREFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Apriso in the 10MM Ulcerative Colitis (UC)
More informationBIOLOGIC AND BIOSIMILAR MEDICATIONS
BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD Crohn s disease and ulcerative colitis are the two main forms
More information5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference
5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference September 18-20, 2017 Washington, DC Biosimilars: Price, Policy & Outlook Ron Lanton III, Esq. President
More informationEffect of Naming on Competition and Innovation. Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013
Effect of Naming on Competition and Innovation Mark McCamish, MD, PhD Global Head Biopharmaceutical Development Washington, DC 10 December 2013 1 FTC Biosimilars Workshop on Naming Proposals and Impact
More informationExpectation for the future and the role of the JP
JP 130 th Anniversary Symposium (15 September, 2016) Expectation for the future and the role of the JP From Academia s perspectives Toru KAWANISHI, PhD Director-General National Institute of Health Sciences
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Overview of the Regulatory Pathway and FDA s Guidance for the Development and Approval of Biosimilar
More informationBIOSIMILARS: ON THE REALM OF REALITY DETERMINANTS OF SUCCESS
1 Originally presented at the 2013 AAPS National Biotechnology Conference - BIOTEC Open Forum Update (see slide #2) 7/14/2013 BIOSIMILARS: ON THE REALM OF REALITY DETERMINANTS OF SUCCESS Ajaz Insight 2
More information8/14/2017 FOLLOW-ON BIOLOGICS: HOW BIOSIMILAR ARE THEY? STEPHANIE A. KLEPSER, PHARM.D. OPTIMED SPECIALTY PHARMACY OBJECTIVES OBJECTIVES
FOLLOW-ON BIOLOGICS: HOW BIOSIMILAR ARE THEY? STEPHANIE A. KLEPSER, PHARM.D. OPTIMED SPECIALTY PHARMACY OBJECTIVES Explain how biosimilars differ from small molecule generic drugs. Discuss the FDA approval
More informationCurrent scenario of biosimilar
2018; 7(7): 188-193 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(7): 188-193 2018 TPI www.thepharmajournal.com Received: 16-05-2018 Accepted: 20-06-2018 Pooja Paul Department of
More informationFDA s Implementation of the Legal and Regulatory Framework for Biosimilars
FDA s Implementation of the Legal and Regulatory Framework for Biosimilars Sally Howard Deputy Commissioner for Policy, Planning, and Legislation 1 What are therapeutic biologics? Many biologics treat
More informationBiosimilar vs. Generic, What s the Difference?
Biosimilar vs. Generic, What s the Difference? Kelly Peddy, PharmD, MPA, BCACP Clinical Pharmacy Specialist Ambulatory Care Memorial Hospital of South Bend A presentation for HealthTrust members December
More informationREFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST Executive Summary Sales for Ulcerative Colitis in Canada In 2012, GlobalData estimated that Canada Ulcerative
More informationInnovative Approaches to Saving Patients Money on Prescription Drug Costs
Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationLAW: Primer on biosimilar agents
AND AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS 2 CPE CREDITS EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM Educational Objectives After participating
More informationSpecialty Drugs: Trends, Challenges and Solutions. Life s brighter under the sun. November2015
November2015 Specialty Drugs: Trends, Challenges and Solutions Join The Conversation, brought to you by Sun Life Financial Group Benefits. Life s brighter under the sun Foreword As someone tasked with
More informationREFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Uceris in the 10MM Ulcerative Colitis (UC)
More informationREFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The below mentioned table presents the key metrics for Crohn s
More information29/04/2016. Biosimilars An NHS perspective. Aim. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016
Biosimilars An NHS perspective Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016 Aim The changing medicines landscape driving patient access to medicines the Biosimilar
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationREFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Simponi in the 10MM Ulcerative Colitis (UC)
More informationThe benefits of biosimilar medicines
Chapter 5 The benefits of biosimilar medicines Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?
More informationCONGRESS ON BIOSIMILARS
TM CONGRESS ON BIOSIMILARS CONGRESS REPORT CARE CONGRESS ON BIOSIMILARS - TORONTO, CANADA - JANUARY 13, 2017 TM 905 891 1900 www.careeducation.ca Community Academic Research Education @wearecare info@careeducation.ca
More informationWhat is the Role of HTA for Biosimilars? Jorge Mestre-Ferrandiz and Adrian Towse, Office of Health Economics
April 2014 Briefing 54 What is the Role of HTA for Biosimilars? Jorge Mestre-Ferrandiz and Adrian Towse, Office of Health Economics This Briefing contains a summary of the main points and conclusions from
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationREFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis
More informationOvercoming Challenges in the Emerging Biosimilar Landscape
Overcoming Challenges in the Emerging Biosimilar Landscape Steven R. Feldman, M.D., Ph.D. Wake Forest University School of Medicine Winston Salem, North Carolina, USA Objectives Identify the safety and
More informationHow to maximize patient access Perspectives from The Netherlands
Budapest, June 13, 2018 How to maximize patient access Perspectives from The Netherlands Vs18f13 Arnold G. Vulto PharmD PhD FCP Professor Em. of Hospital Pharmacy & Practical Therapeutics Erasmus University
More informationas they ordinarily would for a generic. This has been a key factor inhibiting biosimilar uptake.
PEB OVR 6.1 Agenda Item 6 BIOSIMILARS REIMBURSEMENT 1 Purpose of Item 1.1 The Minister (delegate) requests the Pharmaceutical Benefits Advisory Committee (PBAC) provide advice on the following matter(s)
More informationTABLE OF CONTENTS 1. INTRODUCTION 1.1 STUDY DELIVERABLES 1.2 MARKET DEFINITION 1.3 STUDY ASSUMPTIONS 2. RESEARCH METHODOLOGY 2.
TABLE OF CONTENTS 1. INTRODUCTION 1.1 STUDY DELIVERABLES 1.2 MARKET DEFINITION 1.3 STUDY ASSUMPTIONS 2. RESEARCH METHODOLOGY 2.1 INTRODUCTION 2.2 METHOD OF ANALYSIS 2.3 STUDY PHASES 2.4 SECONDARY RESEARCH
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationFormulary Considerations for Biosimilars in healthcare systems
Formulary Considerations for Biosimilars in healthcare systems Ahmed Aljedai, Pharm.D., M.B.A, BCPS, FCCP, FAST Assistant Deputy Minister for Therapeutic Affair, MOH,KSA Disclosure Information Formulary
More informationSwitch Management between Similar Biological Medicines. A Communication and Information Guide for Nurses E U R O P E A N S P E C I A L I S T
Switch Management between Similar Biological Medicines A Communication and Information Guide for Nurses E U R O P E A N S P E C I A L I S T NURSES ORGANISATIONS E U R O P E A N S P E C I A L I S T NURSES
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationEvolving U.S. Biosimilars Landscape
Evolving U.S. Biosimilars Landscape A Medical Affairs Perspective By Thao Sutter and Bryan Katz Syneos Health Consulting 2018 Syneos Health. All rights reserved. Introduction The U.S. biosimilar landscape
More informationProfessor Tore Kristian Kvien, MD, PhD, Norway
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationThe importance of interchangeability in the procurement of medications: Biosimilar case
The importance of interchangeability in the procurement of medications: Biosimilar case ALIMS Congres, Kragujevac, November 6, 2015 Prof. Borut Štrukelj, PhD Brief CV Current position: professor, Pharmaceutical
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationCURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines
CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE The role of Biosimilar Medicines Marc A. Mahl, MD MBA(INSEAD) President, Medicines for Europe Baltimore, 05 th September 2018 patients quality
More informationANONYMOUS, NON-CONTACTABLE NHS WHISTLEBLOWER v NAPP
Case AUTH/2795/9/15 ANONYMOUS, NON-CONTACTABLE NHS WHISTLEBLOWER v NAPP Promotion of Remsima An anonymous, non-contactable NHS whistleblower complained about the promotion of Remsima (infliximab) by Napp
More informationThe Role of Biosimilar Medica2ons in Clinical Prac2ce
The Role of Biosimilar Medica2ons in Clinical Prac2ce Emmanuel Markakis, PharmD Clinical Manager / PGY1 Residency Director Boca Raton Regional Hospital Boca Raton, Florida Objec2ves Define what biosimilar
More informationMANAGEDCAREBIOSIMILARS UPDATE: 2017 POLICY INITIATIVES & FORMULARY IMPACT
MANAGEDCAREBIOSIMILARS UPDATE: 2017 POLICY INITIATIVES & FORMULARY IMPACT Steven Lucio, PharmD, BCPS AVP, Clinical Solutions and Pharmacy Program Development Vizient Irving, Texas Steven G. Avey, MS, RPh,
More informationPerspectives Spring The Drug Pipeline: What s in it and why it matters.
Perspectives Spring 2016 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Author: Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationGlobal biosimilar policy comparison. Overview of biosimilar policies across 9 major markets in the battle to control healthcare sustainability
Global biosimilar policy comparison Overview of biosimilar policies across 9 major markets in the battle to control healthcare sustainability Table of contents I. Introduction... 3 1. Goal... 3 2. Research
More information